PSMA靶向放射性核素配体在mCRPC治疗中的研究进展  

Advances in PSMA-targeted radioligands for the treatment of mCRPC

作　　者：赵玉[1] 马重 滕竞飞 刘东山 艾星 Zhao Yu;Ma Chong;Teng Jingfei;Liu Dongshan;Ai xing(Basic Medical College of China Three Gorges University,Yichang 443000,China;Department of Urology,the Third Medical Center of Chinese PLA General Hospital,Beijing 100080,China;Department of Urology,Renhe Hospital Affiliated to China Three Gorges University,Yichang 443000,China)

机构地区：[1]三峡大学基础医学院,宜昌443000 [2]解放军总医院第三医学中心泌尿外科学部,北京100080 [3]三峡大学附属仁和医院泌尿外科,宜昌443000

出　　处：《中华泌尿外科杂志》2025年第3期237-240,共4页Chinese Journal of Urology

摘　　要：转移性去势抵抗性前列腺癌(mCRPC)对传统治疗耐药,前列腺特异性膜抗原(PSMA)靶向放射性核素治疗成为重要的新兴策略。177Lu-PSMA和225Ac-PSMA等配体治疗在临床研究中显示出可使患者获益,并在与内分泌治疗、化疗、免疫治疗及放疗的联合治疗中展现出潜力。此外,PSMA靶向抗体-药物偶联物、嵌合抗原受体T细胞以及双特异性T细胞连接器等新型治疗手段也在不断探索中。本文主要综述PSMA靶向治疗的研究进展及其临床应用前景。Metastatic castration-resistant prostate cancer(mCRPC)is often resistant to conventional therapies,and prostate-specific membrane antigen(PSMA)-targeted radionuclide therapy has emerged as a promising therapeutic strategy.Ligands such as 177Lu-PSMA and 225Ac-PSMA have demonstrated clinical benefits in ongoing studies and show potential when combined with endocrine therapy,chemotherapy,immunotherapy,and radiotherapy.Additionally,novel therapeutic approaches,including PSMA-targeted antibody-drug conjugates(ADCs),chimeric antigen receptor T-cell(CAR-T)therapy,and bispecific T-cell engagers(BiTEs),are being actively explored.This review summarizes the recent advancements in PSMA-targeted treatment and their clinical applications.

关 键 词：前列腺肿瘤 转移性去势抵抗性前列腺癌 前列腺特异性膜抗原 放射性配体治疗 

分 类 号：R737.25[医药卫生—肿瘤]